GH Research PLC GHRS · SEC Filings

website

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for...

Price19.26

Market Cap1.32 B

Float50.91 M

CountryIE

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 5, 2026

20-F/A

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]

Jul 29, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Feb 27, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 7, 2024

20-F/A

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]

Jun 2, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 9, 2023

News

TYPE

HEADLINE

FILED AT

6-K

GH Research PLC Announces Presentation of Clinical Trial Data at the 39th ECNP Annual Meeting

Oct 9, 2026

6-K

GH Research PLC to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 11, 2026

6-K

GH Research PLC Reports Second Quarter 2026 Financial Results

Aug 6, 2026

6-K

GH Research PLC Announces Results of 2026 Annual General Meeting

Jun 26, 2026

6-K

GH Research Announces Positive Phase 2a Postpartum Depression Results and Upcoming Presentations at CINP 2026

Jun 4, 2026

6-K

GH Research Reports Positive Phase 2b Results for GH001 in Treating Anhedonia in Patients with Treatment-Resistant Depression

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 20, 2026

CORRESP

Form CORRESP - Correspondence

May 15, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 15, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 10, 2025

CORRESP

Form CORRESP - Correspondence

Mar 5, 2025

LETTER

Form UPLOAD - SEC-generated letter

Mar 3, 2025